Yasuo Urata, president of Oncolys BioPharma, reflected on the long development process after the company received approval for a viral therapy targeting esophageal cancer.
The treatment is described as a world-first viral therapy. Urata expressed hope that it will improve quality of life for patients with esophageal cancer.
The approval marks the culmination of extended efforts by the pharmaceutical company based in Japan. Details of the therapy's mechanism were not specified in available reports.
The Japan Times published the account on June 18, 2026.
